Tatyana Dekhtyar

<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir

Teresa I. Ng, Preethi Krishnan, Warren M. Kati et al. · Antimicrobial Agents and Chemotherapy · 2017 · 136 citations · Full text

Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro

Hongmei Mo, Liangjun Lu, Ron Pithawalla et al. · Antimicrobial Agents and Chemotherapy · 2005 · 120 citations · Full text

Viral Replication, Hepatitis C Virus, Viral Hepatitis +12

<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450

Rakesh Tripathi, Daniel E. Cohen, I. Gaultier et al. · Antimicrobial Agents and Chemotherapy · 2014 · 116 citations · Full text

Cytochrome P450 3A4, Viral Hepatitis, Medicine +13

<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir

Teresa I. Ng, Rakesh Tripathi, Thomas Reisch et al. · Antimicrobial Agents and Chemotherapy · 2017 · 87 citations · Full text

O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens

Preethi Krishnan, Rakesh Tripathi, Gretja Schnell et al. · Journal of Hepatology · 2015 · 83 citations

Treatment-emergent Resistance-associated Variants, Pathogenesis, Antiviral Drug Development +11